CommercialPrior AuthLow impact
Namenda XR® (memantine extended-release) (Revised)
Humana·Neurology, Geriatrics, Family Medicine +1 more·Commercial
Effective date
Jan 1, 2024
We identified it
Jun 24, 2026
Summary
Humana revised their prior authorization policy for Namenda XR (memantine extended-release) for moderate to severe Alzheimer's disease. The policy requires confirmation of diagnosis and that patients have tried or cannot use generic immediate-release memantine before approving the extended-release version.
Action Required
Immediately: When prescribing Namenda XR for Alzheimer's patients with Humana Commercial plans, ensure prior authorization is obtained by confirming: 1) Patient has moderate to severe Alzheimer's dementia diagnosis, and 2) Patient has tried or cannot use generic memantine immediate-release tablets. Document both criteria clearly in prior auth requests to avoid denials.